Expertise in
22
conditions

Dr. Mayer N. Fishman

Hematology | Oncology
Tgh Cancer Institute
3140 S Falkenburg Rd, 
Riverview, FL 
Accepting New Patients
Offers Telehealth
Expertise in
22
conditions
Tgh Cancer Institute
3140 S Falkenburg Rd, 
Riverview, FL 

Overview

Mayer Fishman is a Hematologist and an Oncologist practicing medicine in Riverview, Florida.

Dr. Fishman is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Prostatectomy.

Dr. Fishman is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 69 peer reviewed articles and participating in 7 clinical trials. Dr. Fishman is currently accepting new patients.

Graduate Institution

University Of Maryland School Of Medicine

Residency

Barnes-Jewish Hospital , Internal Medicine

Specialties

Hematology
Oncology

Licenses

Internal Medicine in FL

Board Certifications

American Board Of Internal Medicine

Fellowships

Tampa General Healthcare , Internal Medicine

Hospital Affiliations

Tampa General Hospital
Tampa General Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Tgh Cancer Institute
3140 S Falkenburg Rd, Riverview, FL 33578
Other Locations
Tgh Cancer Institute At Riverview
3140 S Falkenburg Rd Ste 301, Riverview, FL 33578

Additional Areas of Focus

Dr. Fishman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Biological, Procedure
Study Drugs: Pembrolizumab, Ziv-Aflibercept
Study Phase: Phase 1
Coordinated High Dose Interleukin-2 (Aldesleukin, Proleukin™) and Pembrolizumab (Anti-PD1, Keytruda™) for Therapy of Metastatic Kidney Cancer
Coordinated High Dose Interleukin-2 (Aldesleukin, Proleukin™) and Pembrolizumab (Anti-PD1, Keytruda™) for Therapy of Metastatic Kidney Cancer
Enrollment Status: Completed
Publish Date: July 02, 2026
Intervention Type: Drug
Study Drugs: Pembrolizumab, Interleukin-2
Study Phase: Phase 2
A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Abiraterone Acetate
Study Phase: Early Phase 1
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase 2 Study of Check Point Inhibitor, Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder
A Phase 2 Study of Check Point Inhibitor, Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder
Enrollment Status: Terminated
Publish Date: July 29, 2022
Intervention Type: Procedure, Drug
Study Drug: Durvalumab
Study Phase: Phase 2
A Phase I/1b Study of Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
A Phase I/1b Study of Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
Enrollment Status: Completed
Publish Date: August 01, 2019
Intervention Type: Drug
Study Phase: Phase 1
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Enrollment Status: Completed
Publish Date: June 13, 2019
View 6 Less Clinical Trials

69 Total Publications

Current Clinical Utility of Gene Expression Panels in Primary Cutaneous Melanoma.
Current Clinical Utility of Gene Expression Panels in Primary Cutaneous Melanoma.
Journal: Cancers
Published: April 24, 2026
Similar Doctors
Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology
Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (14.5 miles away)
813-692-4147
Languages Spoken:
English, Czech, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Lubomir Sokol is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Sokol is highly rated in 55 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sokol is currently accepting new patients.

Expertise in
42
conditions
Dr. Rami S. Komrokji
Hematology | Oncology
Expertise in
42
conditions
Dr. Rami S. Komrokji
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (14.5 miles away)
813-566-0119
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rami Komrokji is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Komrokji is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Sideroblastic Anemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Komrokji is currently accepting new patients.

Expertise in
20
conditions
Dr. Rachid C. Baz
Hematology | Oncology
Expertise in
20
conditions
Dr. Rachid C. Baz
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (14.5 miles away)
813-867-4646
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rachid Baz is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Baz is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Plasmacytoma, Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Aspiration. Dr. Baz is currently accepting new patients.

Frequently Asked Questions about Dr. Mayer N. Fishman

How do I make an appointment with Dr. Mayer N. Fishman?

You can book an appointment with Dr. Mayer N. Fishman by calling their office at 813-844-7585. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mayer N. Fishman a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mayer N. Fishman is classified as an Elite expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mayer N. Fishman specialize in?

While Dr. Mayer N. Fishman is a Hematology, they have specific expertise in Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, and WT1-Related Wilms Tumor Syndromes. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Mayer N. Fishman participate in research or clinical trials?

Yes. Dr. Mayer N. Fishman has published 69 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Dr. Mayer N. Fishman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mayer N. Fishman accept my insurance?

Dr. Mayer N. Fishman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 813-844-7585 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fishman's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 9 Advanced Conditions
View All 54 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile